SCHEMBL1580112

SCHEMBL1580112

N[C@@H](Cc1c[nH]c2ccc([N+](=O)[O-])cc12)C(=O)O

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRA P18433 1/20 0.82
CYP2C19 P33261 1/20 0.78
KMT2A Q03164 3/20 0.67
KDM4E B2RXH2 2/20 0.67
LMNA P02545 2/20 0.67
MAPT P10636 2/20 0.67
TSHR P16473 2/20 0.67
BLM P54132 2/20 0.67
PMP22 Q01453 2/20 0.67
ALDH1A1 P00352 1/20 0.67
CYP3A4 P08684 1/20 0.67
HTR1A P08908 1/20 0.67
ADORA3 P0DMS8 1/20 0.67
ALOX15 P16050 1/20 0.67
NFKB1 P19838 1/20 0.67
HTR2A P28223 1/20 0.67
HTR2C P28335 1/20 0.67
SLC6A4 P31645 1/20 0.67
HTR7 P34969 1/20 0.67
HTR2B P41595 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1580111 1.00 PTPRA (0.82) PTPRACYP2C19KMT2AKDM4ELMNA
Gamma-Aminobutyric Acid SCHEMBL3789958 0.90 PTPRA (0.68) PTPRACYP2C19KMT2AKDM4ELMNA
SCHEMBL30789181 0.90 PTPRA (1.00) PTPRACYP2C19KMT2AKDM4ELMNA
SCHEMBL30381729 0.90 PTPRA (1.00) PTPRACYP2C19KMT2AKDM4ELMNA
SCHEMBL2965137 0.90 PTPRA (1.00) PTPRACYP2C19KMT2AKDM4ELMNA
SCHEMBL3519524 0.90 PTPRA (1.00) PTPRACYP2C19KMT2AKDM4ELMNA
SCHEMBL145392 0.90 PTPRA (1.00) PTPRACYP2C19KMT2AKDM4ELMNA
SCHEMBL5115727 0.90 PTPRA (0.67) PTPRACYP2C19KMT2AKDM4ELMNA
SCHEMBL5115733 0.90 PTPRA (0.67) PTPRACYP2C19KMT2AKDM4ELMNA
SCHEMBL5773295 0.86 PTPRA (0.61) PTPRACYP2C19KMT2AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3788149-B1 A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION AMBRX INC (US) 2025-08-27 EP claimed
EP-3630977-B1 METHODS AND COMPOSITIONS FOR PROMOTING NON-NATURAL AMINO ACID-CONTAINING PROTEIN PRODUCTION AMBRX INC (US) 2024-02-21 EP claimed
US-20260060959-A1 FORMULATIONS WITH REDUCED OXIDATION GENENTECH INC (US) 2026-03-05 US disclosed
US-20260002147-A1 ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2026-01-01 US disclosed
EP-4651906-A1 ANTI-CD70 ANTIBODY-DRUG CONJUGATES Ambrx, Inc. (US) 2025-11-26 EP disclosed
EP-4598586-A1 DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF Ambrx, Inc. (US) 2025-08-13 EP disclosed
US-12385029-B2 Engineered synthase for production of tryptophan derivatives and intransigent substrates CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-08-12 US disclosed
WO-2025041055-A1 ANTI-PSMA ADC CONJUGATE COMPOSITIONS AND METHODS OF USE THEREOF AMBRX, INC. (US) 2025-02-27 WO disclosed
WO-2024241086-A1 PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF AMBRX, INC. (US) 2024-11-28 WO disclosed
WO-2024215515-A1 DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF AMBRX, INC. (US) 2024-10-17 WO disclosed
WO-2024178310-A1 TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF AMBRX, INC. (US) 2024-08-29 WO disclosed
WO-1998051331-A1 SOMATOSTATIN AND SOMATOSTATIN AGONISTS FOR DECREASING BODY WEIGHT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (S.C.R.A.S.) (FR) 1998-11-19 WO disclosed
WO-1998008529-A1 METHOD OF INHIBITING FIBROSIS WITH A SOMATOSTATIN AGONIST BIOMEASURE INCORPORATED (US) 1998-03-05 WO disclosed
US-5686418-A SOMATOSTATIN BIOMEASURE INCORPORATED (US) 1997-11-11 US disclosed
US-5583104-A SOMATOSTATIN ANTITUMOR AGENTS MAYO FOUNDATION FOR MEDICAL RESEARCH AND EDUCATION (US) 1996-12-10 US disclosed
US-5504069-A USING SOMATOSTATIN BIOMEASURE, INC. (US) 1996-04-02 US disclosed
EP-0644893-A4 INHIBITION OF TRAUMA-INDUCED TUMOR GROWTH. BIOMEASURE INC (US) 1995-09-20 EP disclosed
EP-0657174-A1 Use of somatostatin MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 1995-06-14 EP disclosed
EP-0644893-A1 INHIBITION OF TRAUMA-INDUCED TUMOR GROWTH BIOMEASURE, INC. (US) 1995-03-29 EP disclosed
WO-1994018231-A1 INHIBITION OF TRAUMA-INDUCED TUMOR GROWTH BIOMEASURE, INC. (US) 1994-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060959-A1 FORMULATIONS WITH REDUCED OXIDATION LPO, SET, PTMS PTPRA 2900/4885CYP2C19 599/4885KMT2A 3872/4885
US-12385029-B2 Engineered synthase for production of tryptophan derivatives and intransigent substrates WARS1, TPH1, TPH2 PTPRA 3344/4885CYP2C19 1937/4885KMT2A 1560/4885
US-20260002147-A1 ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES INMT, TPH1, TPH2 PTPRA 4506/4885CYP2C19 110/4885KMT2A 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.